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Abstract
Purpose: To investigate the relationship between tear concentration of the homeostatic protein clusterin
(CLU) and dry eye signs and symptoms, and to characterize tear CLU protein.
Methods: Two independent studies were conducted, one in Tucson (44 subjects), the other in Los Angeles
(52 subjects). A cohort study design was employed to enroll patients without regard to dry eye diagnosis. Dry
eye signs and symptoms were assessed using clinical tests. Tear samples were collected by Schirmer strip, and
also by micropipette at slit lamp when possible. CLU from both sample types was quantified by immunoassay.
The relationship between CLU concentration and clinical test scores was determined by Pearson's correlation
coefficient (for individual eyes) and multiple linear regression analysis (including both eyes). CLU was also
evaluated biochemically by western blotting.
Results: In the Tucson cohort, a positive correlation was observed between tear CLU concentration and
results of the Schirmer strip test, a measure of tear flow (p = 0.021 includes both eyes). This result was
corroborated in the Los Angeles cohort (p = 0.013). The mean tear CLU concentration was 31 ± 14 μg/mL (n
= 18 subjects, 33 eyes; range = 7-48 μg/mL). CLU from clinical tear samples appeared biochemically similar
to CLU from a non-clinical tear sample and from blood plasma.
Conclusions: Results support the hypothesis that an optimal concentration of tear CLU is important for ocular
surface health, and that this drops below the effective threshold in dry eye. Tear CLU measurement might
identify patients that could benefit from supplementation. Information about concentration will aid
development of therapeutic dosage parameters.
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A B S T R A C T
Purpose: To investigate the relationship between tear concentration of the homeostatic protein clusterin (CLU)
and dry eye signs and symptoms, and to characterize tear CLU protein.
Methods: Two independent studies were conducted, one in Tucson (44 subjects), the other in Los Angeles (52
subjects). A cohort study design was employed to enroll patients without regard to dry eye diagnosis. Dry eye
signs and symptoms were assessed using clinical tests. Tear samples were collected by Schirmer strip, and also by
micropipette at slit lamp when possible. CLU from both sample types was quantified by immunoassay. The
relationship between CLU concentration and clinical test scores was determined by Pearson's correlation coef-
ficient (for individual eyes) and multiple linear regression analysis (including both eyes). CLU was also evaluated
biochemically by western blotting.
Results: In the Tucson cohort, a positive correlation was observed between tear CLU concentration and results of
the Schirmer strip test, a measure of tear flow (p=0.021 includes both eyes). This result was corroborated in the
Los Angeles cohort (p= 0.013). The mean tear CLU concentration was 31 ± 14 μg/mL (n=18 subjects, 33
eyes; range= 7–48 μg/mL). CLU from clinical tear samples appeared biochemically similar to CLU from a non-
clinical tear sample and from blood plasma.
Conclusions: Results support the hypothesis that an optimal concentration of tear CLU is important for ocular
surface health, and that this drops below the effective threshold in dry eye. Tear CLU measurement might
identify patients that could benefit from supplementation. Information about concentration will aid develop-
ment of therapeutic dosage parameters.
1. Introduction
Dry eye syndrome is a common affliction associated with aging that
affects 5% to 34% of all people globally [1]. According to the definition,
recently revised by the Tear Film and Ocular Surface Society Dry Eye
Workshop II [2], dry eye is “a multifactorial disease of the ocular sur-
face characterized by a loss of homeostasis of the tear film, and ac-
companied by ocular symptoms, in which tear film instability and hy-
perosmolarity, ocular surface inflammation and damage, and
neurosensory abnormalities play etiological roles”. Reduced tear flow
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and/or increased tear evaporation causes tear hyperosmolarity and
desiccating stress, which stimulates inflammation and expression/ac-
tivity of matrix metalloproteinases (MMPs). This can lead to ocular
surface disease characterized by increased apoptosis, desquamation and
barrier disruption, which is visualized as punctate staining with clinical
dyes [3].
Clusterin (CLU2) is a secreted glycoprotein that serves as a “mole-
cular chaperone”. As such it is part of an extracellular quality control
system maintaining proteostasis by binding to misfolded proteins, in-
hibiting their precipitation and participating in their clearance from
bodily fluids as high molecular weight soluble complexes [4–6]. Ex-
perimental immunodepletion of CLU from human blood renders other
plasma proteins susceptible to stress-induced precipitation [7]. CLU is
found in insoluble protein deposits in diseases of amyloid deposition
such as pseudoexfoliation glaucoma and Alzheimer's disease, perhaps
representing an aborted attempt to fulfill the molecular chaperone role
[8]. However, studies show that if CLU attains a critical concentration
threshold, it potently inhibits deposit formation and provides sub-
stantial cytoprotection [8]. CLU is also proteostatic by virtue of its
ability to serve as a potent inhibitor of several MMP family proteinases
[9,10].
An early study characterizing CLU revealed a striking level of ex-
pression in mucosal epithelial cells, as well as several non-epithelial
secretory cell types from a broad range of tissues that form cellular
interfaces with fluid compartments [11]. The results suggested that
localized CLU synthesis might be particularly important for protection
of fluid barrier tissues. CLU protein is found in the apical cell layers of
the ocular surface epithelia [12–14] and mass spectrometric analyses
have consistently identified CLU in human tears (e.g., [15–21]). CLU in
the ocular surface epithelia decreases dramatically in inflammatory
disorders that manifest as severe dry eye [22–24]. Using a mouse model
for desiccating stress that mimics human dry eye, we recently provided
the first causal evidence in support of the idea that tear CLU protects
the ocular surface. We showed that CLU prevent and ameliorates ocular
surface signs of dry eye when present in sufficient amounts in the tears
[25], either endogenously, or when supplemented by topical applica-
tion. Tear CLU concentration was reduced to about 2/3rds of normal in
mice subjected to desiccating stress, dropping below the critical
threshold. This suggested that there is an optimal concentration of tear
CLU needed for ocular surface health, and that this concentration might
drop below the effective threshold in dry eye. If so, supplementation
could be therapeutic.
In this report, we describe the results of two independent but co-
ordinated studies conducted with the common goal to determine for the
first time, the concentration and biochemical characteristics of CLU in
human tears, and to investigate whether changes in these parameters
are correlated with clinical signs and symptoms of dry eye.
2. Methods
2.1. Ethics statement and human subjects
The two studies described herein were compliant with the
Declaration of Helsinki, the Health Insurance Portability and
Accountability Act (HIPAA), and the Institutional Review Boards of the
University of Arizona Tucson and the University of Southern California
(USC; Los Angeles). Informed consent was obtained from all research
subjects after explanation of the nature of the study and possible con-
sequences.
In the first study, patients were recruited in Tucson as part of a
larger investigation ongoing at the University of Arizona headed by Dr.
Mingwu Wang. Patients were enrolled into the study in Dr. Wang's
cornea clinic under the parent protocol, and all patient data and spe-
cimens were collected at this site. After results were obtained from the
Tucson study, a second study was conducted in Los Angeles with the
goal to independently corroborate results of the first. Patients were
enrolled from the cornea clinic at the USC Roski Eye Institute on the
USC Health Sciences Campus under Drs. Martin Heur and Charles
Flowers.
2.2. Study design
We utilized a cohort study design to enroll subjects across the
spectrum of dry eye signs and symptoms. Subjects over 18 years of age
were enrolled as they came into the eye care clinic for a scheduled
appointment. Subjects were enrolled without regard to sex, gender, race
or ethnic origin. Children were not included, since dry eye is a disease
of aging. Chart records of inflammatory or autoimmune disorders of the
ocular surface were recorded for each enrolled subject.
To assess dry eye signs in enrolled subjects, several standard clinical
tests were used (procedures described below). Tests were performed for
both the left and right eyes separately. All test variables are presented
as the mean ± SD. To assess dry eye symptoms, all enrolled subjects
were asked to fill out the Ocular Surface Disease Index, a set of 12
multiple choice questions [26,27].
Tears were collected on Schirmer test strips from both the left and
right eyes separately, and CLU was extracted for analysis (method de-
scribed below). As discussed more in the next sections, these samples
allowed us to obtain a relative measure of CLU concentration. To di-
rectly measure the actual CLU concentration, tear samples were also
collected in Tucson by micropipette, if possible, from both the left and
right eyes separately (discussed more below).
We estimated sample size for our study using data from mouse ex-
periments and from the Tucson clinic. In the published mouse study,
CLU tear concentration was reduced by ∼30% in mice subjected to
desiccating stress [25]. Prior Tucson clinic data for fluorescein staining
on the standard clinical scale of 1–15 was as follows: mean= 6; stan-
dard deviation (SD)=3. Assuming a 30% reduction in means relative
to healthy subjects, this translates to an effect size of 0.6 ((6–4.2)/3).
Thus, to detect a reasonable group mean difference in CLU, testing at a
2-sided alpha= 0.05, with 80% power, and incorporating a 0.5 corre-
lation between eyes (within subject), 34 subjects (68 eyes) per group
would be required. This sample size would also provide 80% power to
detect within-group correlations of 0.40 and higher with 34 subjects
(68 eyes), and 0.29 and higher in a combined sample of 68 (128)
subjects (eyes).
2.3. Clinical tests for dry eye signs
In the Tucson study, four clinical tests were used to assess signs of
dry eye. Three are tests of tear dysfunction: 1) Schirmer strip test, 2)
tear break-up time and 3) tear osmolarity. The fourth test was fluor-
escein staining, which assesses ocular surface damage.
The Schirmer strip test uses calibrated filter paper strips to measure
tear flow [28]. Test strips were purchased from Alcon Laboratories, Inc.
(Fort Worth, TX). To administer the test, the “head” portion of the strip
was placed with gloved hands over the subject's lid margin, at the
junction of the lateral and middle thirds of the lower eyelids, and the
eyes were closed for 5min. The strip was then removed and the pro-
gress of fluid flow onto the body of the strip by passive capillary action
was recorded from the calibration markings. The test was performed
without anesthetic according to the parent protocol, the rationale being
to avoid any possible dilution of the tears with the anesthetic. (Dilution
was a concern of the investigators at the Tucson site since concentration
measurements were planned; whether tear dilution actually occurred
was not specifically investigated.)
2 For each known human gene, the Human Genome Organisation (HUGO)
Gene Nomenclature Committee (HGNC) (http://www.hugo-international.org/
HUGO-Gene-Nomenclature) approves a unique gene name and symbol. HUGO
nomenclature is used for all genes and their products discussed herein.
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Tear break-up time is a measure of tear quality and vulnerability to
evaporation [3]. Briefly, fluorescein was instilled onto the ocular sur-
face and the patient was asked not to blink while the tear film was
observed under a broad beam of cobalt blue illumination. The tear
break-up time was recorded as the number of seconds that elapsed
between the last blink and the appearance of the first dry spot in the
tear film. Tear osmolarity, a measure of salt concentration (due to re-
duced tear aqueous volume), utilized the TearLab device [29,30].
Fluorescein staining was quantified using the standard National Eye
Institute grading system [31]. Briefly, the cornea is divided into 5 areas
(central, superior, nasal, inferior and temporal); punctate fluorescein
staining in each area is graded on a scale of 0–3, with 3 being the most
severe. The scores from all five areas are then summed, for a final score
of 0–15.
In the Los Angeles study (informed by experience obtained with the
Tucson study), a more streamlined set of tests for dry eye signs was
used: 1) the Schirmer strip test and 2) corneal grading for ocular surface
damage assessment. Some minor modifications were made in the
Schirmer strip test to fit the practices of the Los Angeles clinic. First, the
clinic purchased Schirmer strips from a local supplier (HUB
Pharmaceuticals, LLC, Rancho Cucamonga, CA). In addition, the clinic
insisted on use of a local anesthetic for patient comfort (0.5%
Proparacaine Hydrochloride). Corneal grading was used instead of
fluorescein staining, also because this was the practice of the Los
Angeles clinic. Briefly, this involved careful inspection of the ocular
surface for punctate epithelial erosions without the use of stain. Eyes
were graded on a scale of 0–5, with 5 being the most severe.
2.4. Tear sample collection procedures
Following the Schirmer strip test, which was performed on all
subjects enrolled in both the Tucson and Los Angeles clinics, tear-sa-
turated test strips from each eye of a given subject were saved for ex-
traction and analysis of collected tear proteins by placing them in-
dividually into sterile 2-mL centrifuge tubes.
Efforts were made at the Tucson site to also collect tear samples on
all participants by micropipette. This was done at the slit lamp from
each eye, using a fine 5 μL pipette tip point, precisely at the tear lake at
the medial canthal area. In this way, the ocular surface tissues were not
touched or stimulated. Each time, based on the accumulation at this
location, 1 or 2 μL of tears were aspirated from each eye. Some eyes had
an inadequate tear lake for aspiration and hence failed to generate any
tear samples. In general, if it were possible to collect a sample from one
eye of a given individual, it was also possible to collect a sample from
the other eye. However, in some cases, we could obtain samples from
only a single eye of a specific individual. Samples from each eye were
placed in separate 2-mL centrifuge tubes and diluted with PBS to in-
crease stability.
All sample tubes were set on dry ice, then stored at −80 °C until
they were sent on dry ice to the Fini research laboratory at USC.
Samples were stored at −80 °C until analysis.
2.5. Extraction of proteins from Schirmer strips
The measurement of tear volume using the calibration on the
Schirmer test strip is a relative (not an absolute) measurement of tear
volume, meaning it was not possible to calculate the actual con-
centration of CLU. Thus, we chose to compare the amount of CLU
collected from equal volumes of tears by extracting only the “head” of
each strip, each head being equal in size and completely saturated by
tears in all cases. Extraction was performed according to a method
previously described [32]. Briefly, the head was removed from the strip
and placed in a new 2-mL centrifuge tube containing 100 μL of elution
buffer (100mM ammonium bicarbonate, 0.25% NP-40) with addition
of proteinase inhibitors cocktail (Roche, Indianapolis, IN). Proteins
were eluted by incubating the tubes on a rotator overnight at 4 °C,
followed by micro-centrifugation (10,000 rpm, 5min). Protein was
precipitated in acetone, then dissolved in diluent buffer provided with
the Human Clusterin Quantikine ELISA kit (R&D Systems, Minneapolis,
MN).
2.6. CLU quantification
CLU was quantified for each sample (protein solution eluted from a
Schirmer strip head or a sample collected by micropipette) individually
by enzyme-linked immunosorbent assay (ELISA) using the Human
Clusterin Quantikine ELISA kit (R&D Systems). To prepare samples for
analysis, 50 μL (half) of the protein solution eluted from each Schirmer
strip head, or 0.5 μL of each micropipette-collected sample, was sup-
plemented with assay diluent to 100 μL, as specified by the manu-
facturer. Raw ELISA quantification results were compared to a CLU
standard curve, newly constructed each time a set of samples was
analyzed. The resulting values were described in ng/strip head
(Schirmer strip) or ug/mL (micropipette). The former is a comparative
concentration measure; the latter is an actual concentration measure.
2.7. Correlation analysis
De-identified data were analyzed by statisticians from the Southern
California Clinical and Translational Science Institute (SC-CTSI) to de-
termine the association between tear CLU concentration and clinical
test scores. Measurements from the two eyes of a single subject are
often positively correlated, resembling each other more than they do
measurements from the eyes of other subjects. This inter-eye correla-
tion must be accounted for in analysis [33]. Thus, the Pearson corre-
lation coefficient, r, was used to assess the degree of linear association
between the independent variable, CLU amount per strip head, and the
dependent variable, the clinical test score (clinical outcome), for the
right eye and left eye respectively. Then, linear regression with a
random effect model (specifying a random effect for subject) was used
to assess the CLU versus clinical test correlation for both eyes, ac-
counting for repeated measurement from the same individual (i.e., both
left and right eyes from the same participant). All significance tests
were two-sided, and statistical significance was set at P < 0.05. Data
were analyzed using SPSS for Windows (Version 12.0, SPSS Inc., Chi-
cago, IL).
2.8. Western blotting
Proteins in Schirmer strip extracts and tear samples were separated
by SDS-PAGE and transferred to plastic membranes. Membranes were
probed with primary antibody against CLU and developed by chemi-
luminescence with Luminol enhancer solution and peroxide solution
(GE Healthcare UK limited, Buckinghamshire, UK). Images were cap-
tured with a Fujifilm imaging system (LAS-4000; Fujifilm, Tokyo,
Japan).
CLU from clinical samples was compared with CLU derived from
two different non-clinical sources. Natural secreted human serum CLU
was purified in the Wilson lab from discarded human blood according
to an immunoaffinity protocol previously described [34]. In addition,
non-clinical tears were collected from a male subject enrolled in the
USC research laboratory; this individual did not report any dry eye
symptoms. A published tear wash method was utilized to collect this
sample [35]. Briefly, both eyes were washed 6 times (1 drop/time) with
Refresh (Allergan, Irvine, CA) and a total of 110 μL was collected from
the inferior fornix by micropipette and transferred into a sterile poly-
propylene tube.
Two different CLU antibodies were used to probe the western blots.
One was a rabbit polyclonal antibody (Catalog no. Ab69644, from
Abcam, Cambridge, MA) raised against a synthetic peptide matching a
sequence near the C-terminus of the human CLU beta-chain. The second
antibody was a goat polyclonal antibody raised against mouse CLU
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(catalog no. sc-6420, from Santa Cruz Biotech, Dallas, Texas), re-
commended for detection of mouse, rat and human CLU (Santa Cruz
Biotechnology, Dallas, TX). The epitope recognized by the antibody
maps at the C-terminus of the CLU alpha-chain. (See Fig. 2A for a
graphic of CLU structure showing the two protein chains).
3. Results
3.1. Characteristics and clinical test scores of study subjects
Characteristics and clinical test scores of the subjects from the two
different studies are compiled in Table 1.
A total of 44 subjects were enrolled in the Tucson cohort. One la-
boratory worker quantified CLU collected on individual Schirmer test
strips for the first 16 patients enrolled (group A), while a second la-
boratory worker performed this task for samples from the rest of the
patients (group B). Subjects for which it was possible to also obtain tear
samples were a subset of the second set of patients (subgroup B1).
A total of 52 subjects were enrolled in the Los Angeles cohort. This
time, only a single laboratory worker quantified CLU collected on the
individual Schirmer test strips, with determinations for all samples
done at the same time. Thus, there was no need to split the cohort into
groups.
3.2. Tear CLU concentration and clinical test outcome correlation
The mean CLU protein amount extracted from individual Schirmer
strip heads for both the Tucson cohort and the Los Angeles cohort is
compiled in Table 2. The results for Tucson group A and group B were
systematically different (partially because of use of two different
standard curves) and it was realized that they could not be pooled. This
was the reason for maintaining the two groups as separate.
Tucson group A was too small (n=16) for a valid statistical ana-
lysis, thus analyses were performed using data from group B only,
which was close in size (n=28) to our power estimate. There was no
significant correlation between CLU amount and the Schirmer test score
for the right eye in Tucson group B (r= 0.163, slope=0.28,
p=0.406). However, there was a significant positive correlation be-
tween CLU amount and the Schirmer test score for the left eye
(r= 0.62, p= 0.013). In addition, a significant positive correlation was
observed when the eyes were analyzed together by linear regression
(slope estimate= 0.45, 95%CI=0.07–0.82, p=0.021). Correlations
of CLU amount to other clinical test results were not significant.
Analysis of data from the Los Angeles cohort was done in the same
way as the Tucson cohort. There was no significant correlation between
the CLU amount per strip head and Schirmer test scores for the right eye
(r= 0.172, p=0.224). However there was a statistically significant
positive correlation for the left eye (r= 0.362, p=0.008). In addition,
a significant positive correlation was observed when the eyes were
analyzed together by linear regression (slope estimate= 0.42,
95%CI=0.09–0.75, p=0.013).
The compiled data for corneal grading was quite discontinuous,
which we attribute to the short scoring range of this test; thus statistical
analysis was not performed. Correlation of the CLU amount per strip
head to questionnaire test results was not significant.
An example of the Pearson correlation analysis scatter chart results
is shown in Fig. 1. Results for the linear regression analysis of both the
Tucson and Los Angeles studies are compiled in Table 3.
These results, corroborated in two independent studies, indicate
that CLU concentration is positively correlated with tear flow, so that a
decrease in CLU concentration indicates a decrease in tear flow, a
clinical outcome that is a sign of dry eye disease.
3.3. Actual concentration of tear CLU
The actual volume of tear samples collected by micropipette from
Tucson group B1 patients was measured, making it possible to de-
termine the actual CLU tear concentration. Table 4 summarizes the
ELISA data. The mean ± SD CLU concentration was 31 ± 14 μg/mL
Table 1
Characteristics and clinical test scores of study subjects.
Number of Subjects Tucson Cohort Los Angeles Cohort
n=44 n=52
Group A Group B
n=16 n=28 Subgroup B1
n=18
Tear Sampling Method Schirmer strip Schirmer strip Micropipette in addition to Schirmer strip Schirmer strip
Mean Age (range) 58.7 years (29–81) 65.9 years (39–86) 68.2 years (53–81) 61.9 years (24–95)
Sex (Male/Female) 2/14 7/21 6/12 21/31
Autoimmune Diagnosis 0 1 1 11
Dry Eye Signs (Mean ± SD)
Schirmer (mm wetting, 5 min) 12.9 ± 11.9 14.1 ± 11.1 15.8 ± 11.9 11.16 ± 9.3
Tear Break-Up (seconds) 5.9 ± 3.3 5.6 ± 3.3 6.0 ± 3.5 n/a
Osmolarity (mOsm/L) 302.4 ± 14.3 302.4 ± 15.7 301.5 ± 10.3 n/a
Fluorescein (0–15 scoring scale) 5.0 ± 4.5 5.1 ± 3.0 5.1 ± 3.1 n/a
Corneal Grade (0–5 scoring scale) n/a n/a n/a 0.5 ± 0.76
Dry Eye Symptoms (Mean ± SD)
Questionnaire (1–100 scoring scale) 41.3 ± 21.3 31.8 ± 26.4 26.0 ± 25.3 31.4 ± 25.2
SD= standard deviation from the mean.
Autoimmune diagnoses included Sjögren's syndrome, rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, and non-specified autoimmune disease.
The following test scores for dry eye signs are considered as “normal”: Schirmer test> 15mm (with or without anesthetic), tear break-up time > 10 s, tear
osmolarity of< 296 mOsm/L, fluorescein staining score < 2, corneal grade= 0.
Higher scores on the questionnaire represent greater disability.
Table 2
Quantification of CLU protein extracted from Schirmer strip heads.
Tucson Cohort Los Angeles Cohort
Group A Group B
Number of Subjects (Eyes) n=16 [32] n=28 [55] n=52 (104)
Mean CLU per Strip Head (ng) 1.8 ± 0.7 13.7 ± 3.9 15.2 ± 5.1
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(n=18 subjects; 33 eyes; range=7–48 μg/mL; in one subject, tear
collection was possible from only one eye).
3.4. Tear sample collection method correlation
The fact that tear samples were collected by both Schirmer test strip
and micropipette for subgroup B1 of the Tucson B cohort provided an
opportunity to compare the two methods to determine their equiva-
lence. The correlation for the right eye was not significant (r= 0.33,
slope=0.17, p=0.192); however the correlation for the left eye was
significant (r= 0.62, slope= 0.31, p= 0.013). There was also a sig-
nificant correlation between CLU amount collected by the two methods
analyzing across both eyes with adjustment for repeated measures as
shown in Table 5 (slope estimate= 0.18, 95% CI= 0.02–0.35,
p=0.032).
These results indicate that measurement of tear CLU concentration
by the two tear collection methods correlate with one another.
3.5. Biochemical Characterization of Tear CLU
Western blot analysis was performed on tear samples to assess
biochemical characteristics of tear CLU. Representative results are
shown in Fig. 2. First, a schematic of CLU structure is provided as an aid
Fig. 1. Correlation Analysis. An example of a correlation analysis result is
shown. Pearson correlation coefficient, r, was used to assess the degree of
correlation between Schirmer test results and the amount of clusterin protein on
the Schirmer strip head for each patient in the Los Angeles cohort.
A) The scatter graph illustrates the range of data distribution for the left eye.
The correlation is statistically significant (R=0.362, p= 0.008).
B) The scatter graph illustrates the range of data distribution for the right eye.
The correlation is not statistically significant (R=0.172, p=0.224).
Fig. 2. Biochemical characterization of tear CLU.
A) Predicted structure of secreted human CLU (adapted from Refs. [6,76,77]).
Secreted CLU exhibits an apparent mass of 75–80 kDa by SDS-PAGE, although
the actual mass is ∼58–63 kDa. It is composed of two polypeptide chains de-
rived from an intracellular precursor. In the first processing step, the 22-mer
secretory signal peptide is cleaved from the 449-amino acid precursor. Subse-
quently the chain is cleaved again between Arg227-Ser228 to generate an
alpha-chain and beta-chain of approximately equal length. These are assembled
in anti-parallel fashion and linked at the cysteine-rich center by five disulfide
bridges (black lines) to generate a heterodimeric molecule with four “arms”.
Amphipathic alpha-helices (yellow ovals) located near the ends of each of the
otherwise disordered arms are thought important for binding to hydrophobic
regions exposed on denatured proteins and for insertion into lipid structures.
Sites for N-linked glycosylation (white spots) are located around the cysteine-
rich center of each chain resulting in a molecule that is 17–27% carbohydrate
by weight. Amino acid numbering for the N- and C-termini, the cleavage sites,
and the sites for N-linked glycosylation are indicated, as in Ref. [78]. Schematic
originally published in Ref. [36], used with permission.
B to E) Western blots of purified human blood serum CLU and human tear CLU
samples probed with CLU antibodies are shown. The blots in panels B, D, E
were probed with a polyclonal antibody raised against a synthetic peptide
matching a sequence near the C-terminus of the CLU beta-chain (see schematic,
panel A). The blot in panel C was probed with a polyclonal antibody that re-
cognizes an epitope mapping to the C-terminus of the CLU alpha-chain (see
schematic, panel A; more details on the antibodies in the Methods section).
Beta-MeOH=beta-mercaptoethanol. R= right eye, L= left eye; CLU amounts
loaded on gels were determined by ELISA; The electrophoretic position of
molecular size standards (in kDa) is indicated.
B) Purified human blood serum CLU, 20 ng loaded in each lane.
C) Tears from a non-clinical subject without dry eye symptoms, collected by the
eye wash method described in the Methods section. Ten uL was loaded in each
lane.
D) Tear samples collected by pipette from two of the Tucson cohort subgroup
B1 patients with dry eye signs and symptoms. The arrow indicates the 15 kDa
doublet. Patient 48R: questionnaire score= 35; Schirmer score= 5, CLU
loaded=31 ng.
Patient 49R: questionnaire score=37; Schirmer score= 8, CLU
loaded=26 ng.
E) Schirmer strip elution samples from the Los Angeles cohort patients with a
range of OSDI questionnaire and Schirmer strip test scores. Clinical test scores
and expected CLU amounts loaded per lane according to ELISA assay are in-
dicated below.
Patient F8L: questionnaire= 14.6; Schirmer=25, CLU=6 ng.
Patient H3L: questionnaire= 3.6; Schirmer= 15, CLU=8 ng.
Patient H6L: questionnaire= 68.2; Schirmer= 4, CLU=7 ng.
Patient H18L: questionnaire= 27.1; Schirmer=27, CLU=7 ng.
Patient F12R: questionnaire= 75.0; Schirmer= 4, CLU=6 ng.
Patient H19L: questionnaire= 4.2; Schirmer= 19, CLU=6 ng.
Patient H23R: questionnaire= 11.4; Schirmer=16, CLU=6 ng.
Patient H8R: questionnaire= 22.2; Schirmer= 16, CLU=6 ng.
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to understanding the analysis and results (Fig. 2A). CLU derived from
the tears of a non-clinical subject exhibited an apparent size of
∼75 kDa (Fig. 2B), the apparent size typical for CLU obtained from
various bodily fluids [36]. When the sample was reduced by addition of
beta-mercaptoethanol to break the disulfide bonds in the CLU molecule,
tear CLU appeared as a single band migrating at about 37 kDa, con-
sistent with dissociation into two polypeptide chains of approximately
equal size (only one of which was recognized by the antibody used to
probe the western blot) (Fig. 2B). This electrophoretic behavior was
indistinguishable from human serum CLU (Fig. 2C). The small amount
of CLU that did not dissociate into two polypeptide chains after treat-
ment with beta-mercaptoethanol is typically observed, and represents
unprocessed protein. CLU from one of the two micropipette-collected
samples analyzed from Tucson cohort subgroup B1 appeared to be
cleaved at the C-terminus of the beta chain, generating two small
fragment of ∼15 kDa that were bound by the CLU antibody (Fig. 2D).
This would remove one of the C-terminal amphipathic helices, raising
the intriguing possibility that it is an inactivating cleavage. However,
this cleavage was not identified in 8 different tear samples eluted from
Schirmer strips collected from the Los Angeles cohort (Fig. 2E, thus,
may not be of general significance. In addition, no higher molecular
weight aggregates that might represent CLU bound to denatured client
proteins were evident in any of the samples.
These results indicate that tear CLU is biochemically similar to the
form of CLU found in blood, and is not substantially different in the
tears of patients with signs and symptoms of dry eye.
4. Discussion
CLU is an important component of the quality control system in
bodily fluids that maintains proteins, also called “proteostasis” [4–6].
We recently demonstrated, using a mouse model for desiccating stress,
that CLU prevents and ameliorates ocular surface signs of dry eye dis-
ease if present in sufficient amounts in the tears. However, when CLU
tear concentration dips below a critical threshold, the ocular surface
became vulnerable [25]. Our results suggested that tear CLU needed for
health of the ocular surface might become limiting in human dry eye
disease, and that topical supplementation might be therapeutic. The
current study investigated whether tear CLU concentration correlates
with dry eye signs and symptoms in people. Consistent with our hy-
pothesis, we found that CLU concentration is positively correlated with
Schirmer strip test results. Lower CLU concentration indicates a de-
crease in tear flow, a clinical outcome that is a sign of dry eye disease.
This result was corroborated in two independent studies. We further
report a tear CLU concentration of 31 ± 14 μg/mL (n=18 subjects; 33
eyes; range= 7–48 μg/mL), determined by ELISA using tear samples
from patients with a broad range of test scores for dry eye signs and
symptoms. Finally, we show that tear CLU is biochemically similar to
CLU from blood plasma. CLU present in clinical tear samples is also
biochemically similar to non-clinical samples, suggesting that the pro-
tein in clinical tears is functional, even when concentration is reduced.
CLU concentration varies widely in different human bodily fluids.
Table 6A summarizes information about this, derived from the scientific
literature. The value determined here by ELISA of ∼30 μg/mL for
human tear CLU is about 3-fold lower than the most recently reported
value of 101 ± 42 μg/mL for human blood serum, also determined by
ELISA [37]. CLU has previously been identified in tear proteomics
profiles of normal subjects [15,17–19,38], dry eye subjects [39], and
subjects with pterygium, Sjögren's syndrome and diabetes [16,40,41],
however its concentration has never been determined. Table 6B sum-
marizes information taken from the scientific literature that provides
context to other tear proteins. A small number of highly abundant
proteins are estimated to comprise more than 90% of the total tear
protein by weight, including lysozyme (LYZ), lactoferrin (LTF) tear li-
pocalin (LCN1) and lacritin (LACRT) [42]. However, the remaining
10% is highly complex; in the most comprehensive mass spectrometry
list, 1543 tear proteins were identified [17]. At ∼30 μg/mL, CLU
abundance is substantially lower than that of the major tear proteins
(e.g.,∼50 fold less than LCN1 and∼10-fold less than LACRT), but near
the upper end of abundance for the other proteins. This is consistent
with the hypothesis that there is an optimal concentration of tear CLU
needed for ocular surface health.
Both reduced and elevated levels of CLU are associated with disease
states. The former likely represents dysfunction, and the latter reflects a
compensatory stress response, which may or may not be sufficient to
bring CLU to the necessary level [43]. While we report reduced CLU
concentration associated with reduced tear flow here, elevated CLU in
the saliva has been associated with Sjögren's syndrome [44,45], a dis-
ease that also manifests as dry eye [46]. Low plasma CLU concentration
is associated with an adverse prognosis in patients with chronic heart
failure independent of traditional cardiovascular risk factors and po-
tential confounders [47]. An increased CLU concentration is associated
Table 3
Association between amount of CLU protein extracted from Schirmer strip
heads and clinical test results for dry eye, adjusted for repeated measures.
Clinical Test Cohort Group Slope estimate (95% CI) P-value
Schirmer Tucson B 0.45 (0.07–0.82) 0.021*
Los Angeles 0.42 (0.09–0.75) 0.013*
Fluorescein Tucson B 0.03 (0.06–0.12) 0.499
Tear Break-Up Tucson B −0.07 (−0.18–0.04) 0.219
Osmolarity Tucson B −0.04 (−0.77–0.68) 0.903
Questionnaire Tucson B 0.09 (−0.23–0.42) 0.573
Los Angeles −0.08 (−0.51–0.34) 0.699
* denotes a statistically significant association.
Table 4
CLU concentration in tear samples from tucson cohort subgroup B1.
Number of Subjects (Eyes) n=18 [33]
Mean CLU Concentration (ug/mL) 31 ± 14
Table 5
Association between CLU protein amount extracted from
Schirmer strip heads and CLU protein concentration in
tears.
Slope estimate (95% CI) P-value
0.18 (0.02–0.35) 0.032*
* denotes a statistically significant association.
Table 6A




438 ± 235 [63]
Blood serum
35–105 [64]
111 ± 50 [63]
340 [65]
325 ± 100.3 [66]
101 ± 42 [37]
52.8 ± 0.8 (men) [67]







0.8 ± 0.5 [66]
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with severity, pathology, and progression of Alzheimer's disease [48]
and cognitive impairment [49]. However, functional analyses suggest
reduced secretion of CLU protein as the mode of action for three of the
examined CLU mutations associated with Alzheimer's disease [50]. The
fact that CLU concentration in cerebrospinal fluid is quite low, sug-
gested that the levels could be easily overwhelmed in disease and
prompted the proposal that CLU supplementation might be of ther-
apeutic value in Alzheimer's disease [50]. Our findings here support the
idea that supplementation might be of value for dry eye disease as well.
The range of tear CLU concentrations measured here of 7–48 μg/mL
provides a starting point around which to design a dose range for to-
pical supplementation in clinical trials.
An interesting finding of this study was the consistent observation
that a reduction in the Schirmer test for tear flow correlated to a re-
duction in tear CLU concentration for the left eye, but not for the right.
Perhaps of relevance is the report that cataracts and skin cancers appear
on the left side of the face in North America at a greater frequency than
on the right. Since the opposite correlation is observed in countries that
drive motor vehicles on the other side of the road, it has been theorized
that greater sun exposure through the driver-side window accelerates
the correlated pathologies [51]. The ocular surface epithelia can also be
damaged by sun exposure [52], thus perhaps something similar can
explain our results. While results in the right eye were not statistically
significant in our study, we observed the same correlative trend as in
the left eye. We suspect that the right eye data would also become
statistically significant in a study with a larger sample size.
Why would CLU concentration be lower in patients with reduced
tear flow? To answer this question, it is helpful to consider where CLU is
synthesized. CLU mRNA appears in RNA profiles of the human lacrimal
glands [55,56], meibomian glands [56] and accessory lacrimal glands
of Wolfring [57] and CLU protein is localized to CD31-positive en-
dothelial-like cells in the lacrimal gland of mice [58]. Lacrimal gland
dysfunction leading to aqueous-deficient dry eye might also cause a
reduction in CLU protein secretion, as has been suggested for LCN1 and
LACRT [38].
Shedding and lysis of apical epithelial cells also contribute to the
tear protein profile [42]. CLU mRNA is expressed throughout the cor-
neal epithelium, but the protein product is found in humans [12–14,59]
and mice [10] only in the apical cell layers. When these mucosal
epithelial cells undergo squamous metaplasia in dry eye, CLU protein is
depleted [60]. This would translate into a lower concentration of CLU
in the tears.
There has been much interest in developing a tear protein bio-
marker profile for dry eye and other ocular surface diseases [38,42].
Two recent studies compare relative CLU levels in subjects with and
without dry eye. The first suggested that the tear CLU concentration
was reduced in type 2 diabetic patients with dry eye [41]. The second
study suggested that tear CLU could serve as a biomarker for Sjögren's
syndrome patients with dry eye [40]. However, in both cases, a very
small number of samples were pooled and analyzed as a group, and the
analyses were not quantitative. Tear CLU was reported as non-detect-
able in the normal samples from the second study [40], which is not
consistent with the findings reported here and in other publications
[15,17–19,38]. Our current study is the first that is sufficiently powered
statistically to achieve a meaningful comparison of tear CLU levels in
normal and dry eye subjects. The range of CLU concentrations (as ap-
parent in Table 2 and Fig. 1) is typical of biological samples; however, if
CLU reduction corresponds only with one type of dry eye (such as
aqueous deficient), this would increase variability. Thus, tear CLU
concentration could probably not be used to diagnose dry eye (unless it
becomes possible to stratify for dry eye subtype), but still might serve as
a proxy for assessing efficacy of investigational new drugs in clinical
trials powered with sufficient number of subjects for statistical sig-
nificance. It might also be used to identify patients that could benefit
from CLU supplementation therapy.
In this study, samples were collected without topical anesthesia
(Tucson cohort) and with topical anesthesia (Los Angeles cohort). The
question of topical anesthetic use has been investigated in numerous
publications and although tear secretion generally decreases, there are
many associated variables [61]. In our study, the mean Schirmer test
scores were quite similar (Table 1) and in both cases, a significant
correlation with CLU concentration was observed. In addition, the
correlation between CLU concentration measurement by Schirmer strip
sampling without anesthesia, and pipette sampling (Table 5), which
would not stimulate reflex tearing as performed in this study, suggests
that anesthesia was not a confounding factor in our results. The use of
anesthesia is more comfortable for the patient, providing for a better
experience. Sampling of tears by Schirmer test strip is more acceptable
to the patient than the pipette method, and has the advantage of being
part of a routine clinical work-up.
Why was a significant correlation observed only with the Schirmer
test, and not the other tests performed for signs and symptoms of dry
eye? The Schirmer strip test measures tear flow, which is reduced in
“aqueous-deficient” dry eye, characterized by a reduction in the se-
cretions from the lacrimal glands that produce the aqueous component
of the tears [53]. Thus, a reduction in CLU concentration may corre-
spond best with aqueous deficient dry eye. Since no reliable tests exist
to diagnose dry eye subtype at this time, this can only be conjecture
[3,54].
5. Conclusions
Our previous work in a mouse model for dry eye disease suggested
that reduction of tear CLU below a critical threshold results in ocular
surface vulnerability to stress [25]. Results reported here support the
hypothesis that an optimal concentration of tear CLU is important for
ocular surface health, and that this concentration drops below the ef-
fective threshold in dry eye. Tear CLU measurement might identify
patients that could benefit from supplementation. Information about
concentration, reported here for the first time, will be valuable for
developing therapeutic dosage parameters.
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